Short answer
Cencora (COR) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Earnings release covers Cencora’s fiscal quarter ended June 30, 2026.
Cencora 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Earnings release covers Cencora’s fiscal quarter ended June 30, 2026
- Full financial results and management commentary contained in Exhibit 99.1
- August 5, 2026 release provides the market’s primary update on quarterly performance
Item 7.01 · Regulation FD Disclosure
- Conference call scheduled August 5, 2026 at 8:30 a.m. Eastern
- Discussion covers fiscal quarter ended June 30, 2026 results and related matters
- Investor slides and webcast available at investor.cencora.com
Item EX-99.1 · Exhibit EX-99.1
- Fiscal Q3 revenue $84.8B, up 5.1%; adjusted EPS $4.48, up 12.0%, signaling strong operating momentum
- Adjusted EPS guidance raised to $17.75–$17.95 from $17.70–$17.90, reflecting confidence in fiscal 2026 execution
- U.S. segment operating income up 15.9%, supported by OneOncology and pharmaceutical volume growth
- Net interest expense rose to $140.7M from $81.8M, reflecting acquisition financing through senior notes and variable-rate loans
- $1B share repurchase and $0.60 quarterly dividend support shareholder returns; diluted shares declined 0.7% year over year
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cencora 8-K filings
Get the next COR 8-K as it lands
Follow COR for push alerts, or ask the research agent what this filing means.